Patent applications published 9 February 2011

Published: 11-Mar-2011

Selected patent applications from the weekly European Patents Bulletin


  • Stable crystal modifications of DOPC
    Merck Patent 2280691*

  • Tablet comprising eprosartan mesylate
    LEK Pharmaceuticals 2280692*

  • Liquid and freeze-dried formulations
    Ipsen Pharma 2280693*

  • Humidity-resistant drug formulations and methods of preparation thereof
    Dexcel Pharma Technologies 2280694*

  • Hydroxytyrosol benefits mitochondria
    DSM IP Assets 2280695*

  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of diseases related thereto
    Arena Pharmaceuticals 2280696*

  • Oral liquid compsns of rhein or diacerein
    Wockhardt Research Centre 2280697*

  • Method for inhibiting the growth of bacteria
    Mead Johnson Nutrition Co 2280698*

  • Novel estrogen receptor ligands
    Karo Bio 2280699*

  • Combinations of dronedarone with at least one diuretic, and therapeutic use thereof
    Sanofi-Aventis 2280700*

  • Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalisation or of mortality
    Sanofi-Aventis 2280701*

  • Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
    Sanofi-Aventis 2280702*

  • Use of NPY Y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
    University of Copenhagen 2280703*

  • Oxymethylene aryl compounds and uses thereof
    Metabolex 2280704*

  • Novel compounds
    Glaxo Group 2280705*

  • Lipoprotein lipase activating compsns comprising benzene derivatives
    Otsuka Pharmaceutical Factory 2280706*

  • Alpha2B and alpha2C agonists
    Allergan 2280707*

  • MMP-2 and/or MMP-9 inhibitor
    Otsuka Pharmaceutical 2280708*

  • Treatment of hepatitis C virus infections with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha-2A/2B and ribaviron
    Vertex Pharmaceuticals 2280709*

  • Novel treatment of heart diseases
    Axiogenesis 2280710*

  • Methods, dosage form and kits for administering ziprasidone without food
    Pfizer 2280711*

  • Fluocinolone formulations in a biodegradable polymer carrier
    Warsaw Orthopedic; Medtronic 2280712*

  • Methods and kits for the treatment of inflammatory bowel disorder conditions
    Procter & Gamble 2280713*

  • Compsns comprising anrnox-inhibitors for the inhibition of active oxygen species
    Nu Skin International; NOX Technologies 2280714*

  • Silicia for the inhibition of a protease
    Ineos Healthcare 2280715*

  • Agents and methods for treatment of anxiety disorders
    Yeda Research and Development Co at the Weizmann Institute of Science 2280716*

  • Therapeutic agent for anaerobic diseases
    Anaeropharma Science 2280717*

  • Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
    Biopharmacopae Design International 2280718*

  • Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
    Ipsen Pharma 2280719*

  • Collagen-binding synthetic peptidoglycans, preparation and methods of use
    Purdue Research Foundation 2280720*

  • Indoleamine 2,3-dioxygenase based immunotherapy
    Herlev Hospital 2280721*

  • Method of treating degenerative diseases
    Orthologic 2280722*

  • Zona pellucisa binding peptides, expression vectors, compsns and methods for species-specific immunocontraception of animals
    Auburn University 2280723*

  • Compsns for treating an inflammatory autoimmune condition
    TXCell 2280724*

  • Antiviral nutraceutical
    Marine Biotechnology Australia 2280726*

  • Vaccine compsns for the treatment of dengue fever and uses thereof
    Cytos Biotechnology 2280727*

  • Combined measles-human papilloma vaccine
    Cadila Healthcare 2280728*

  • Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
    Fondazione Centro San Raffaele del Monte Tabor; Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt 2280730*

  • Anti-human immunodeficiency antibodies and uses thereof
    Tecnion Research and Development Foundation 2280731*

  • Antibodies to granulocyte-macrophage colony-stimulating factor
    Kalabios Pharmaceuticals 2280732*

  • Maintenance therapy regimen for treating acne
    Galderma Research & Development 2280733*

  • Factor IX conjugates with extended half-lives
    Celtic Pharma Peg 2280734*

  • Agents for detecting and imaging cell death
    Cambridge Enterprise 2280735*

  • Fatty acid imides and uses thereof
    Yissum Research Development Co of the Hebrew University of Jerusalem 2280934*

  • 4-trimethylammonio-butyrates as CPT2 inhibitors
    F Hoffmann-La Roche 2280935*

  • Ether-amide type compounds, preparation method and uses
    Rhodia Operations 2280936*

  • Aliskiren monofumarate and processes for preparation thereof
    Teva Pharmaceutical Industries 2280937*

  • A process for preparing teriflunomide
    Alembic 2280938*

  • Novel N-(2-amino-phenyl)-acrylamides
    F Hoffmann-La Roche 2280940*

  • (Hetero)aryl cyclohexane derivatives
    Grünenthal 2280941*

  • Indolesulphonyl protecting groups for protection of guanidino and amino groups
    Lonza 2280942*

  • New substituted spiro(cycloalkyl-1,3’-indol)-2’(1’H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors
    Almirall 2280943*

  • Process for the preparation of amides
    Syngenta 2280944*

  • Trisubstituted pyrazoles as acetylcholine receptor modulators
    Janssen Pharmaceutica 2280945*

  • 4-carboxamide indazole derivatives useful as inhibitors of P13-kinases
    Glaxo Group 2280946*

  • Production of 1,7’-dimethyl-2’-propyl-2,5’-bi-1H-benzimidazole
    Boehringer Ingelheim International 2280947*

  • Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
    Mitsubishi Tanabe Pharma 2280948*

  • Process for the preparation of benzo-fused heteroaryl sulphamates and crystalline form of N-((2S)-6-chloro-2,3-dihydro-L,4-benzodioxin-2-yl) methyl sulphamide
    Janssen Pharmaceutica 2280950*

  • Processes for the preparation of benzo-fused dioxin derivatives
    Janssen Pharmaceutica 2280951*

  • Thienopyridione derivatives as AMP-activated protein kinase (AMPK) activators
    Merck Patent 2280952*

  • New substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
    Almirall 2280953*

You may also like